Synergistic effects of ginsenoside Rg3 and cyclophosphamine on tumor growth and angiogenesis in lung cancer

Li Hang¹*, Wang Jun², Guan Yanfeng³, Yang Wenjun⁴, Aiying¹ Suo Aiying¹, Chu Meihua¹, Wang Chenyu¹, Jiang Jing¹, Zhai Shengping¹ and Mao Qishan⁵

¹Department of Respiratory Medicine, Yantai Yuhuangding Hospital, Yantai City, China.
²Department of Respiratory Medicine, Lai Zhou People’s Hospital, Yantai City, Shandong Province, China.
³Medical Department, Haigang Hospital of Yantai, Yantai City, Shandong Province, China.
⁴Neurosurgery Department, Yantai Yuhuangding Hospital, Yantai City, China.
⁵Medical Department, Yantai Yuhuangding Hospital, Yantai City, China.

Accepted 13 July, 2011

To evaluate the effectiveness of ginsenoside Rg3 alone or in combination with cyclophosphamide (CPA) on tumor growth and angiogenesis in human lung cancer, 54 female athymic mice were transplanted with lung cancer cells (A549) which then were randomly divided into 4 groups: Ginsenoside Rg3 group, CPA group, ginsenoside Rg3 plus CPA group and control group. Ginsenoside Rg3 of 3.0 mg/kg (once/day for 10 days) and CPA of 20.0 mg/kg (once/day for 10 days) were intraperitoneally given to mice for consecutive 10 days. Seven mice selected from each group were sacrificed 18 days later. The survival time of the remaining 7 mice in each group was recorded. The life elongation rate, proliferating cell nuclear antigen labeling index (PCNALI), expression of vascular endothelial cell growth factor (VEGF) and microvessel density (MVD) in the tumor tissues were evaluated. The quality of life of mice with administration of ginsenoside Rg3 alone or ginsenoside Rg3 plus CPA were better with longer survival time, when compared with other groups. The PCNALI, MVD and VEGF expression in mice of the treated groups were significantly lowered when compared with that of the control group. Additionally, the MVD of mice in groups with treatment of ginsenoside Rg3 alone or ginsenoside Rg3 plus CPA were lower than that in the CPA group. Tumor growth and angiogenesis in lung cancer were profoundly inhibited by ginsenoside Rg3 alone or in combination with CPA. The synergistic anticancer effects of ginsenoside Rg3 and CPA improved the survival time in lung cancer.

Key words: Ginseng, cyclophosphamide, angiogenesis, lung cancer.

INTRODUCTION

With the development of Chinese herbal medicine, more and more researchers are interested in the exploitation of novel anticancer components in herbs. Ginsenoside Rg3, the major active component of ginseng has high anticancer activity. Studies have indicated its suppressive effects on the angiogenesis in Lewis cancer (Lee et al., 2009), breast cancer (Zhang et al., 2008) and on invasion and metastasis of intestinal adenocarcinomas and B16 melanoma (Liu et al., 2004; Mochizuki et al., 1995; Iishi et al., 2004) as well as proliferation of prostate cancer cells (Kim et al., 2004; Keum et al., 2003). Recently, evidence has disclosed the therapeutic effects of continuous low dose chemotherapy combined with other inhibitors of angiogenesis (Hanahan et al., 2000; Klement et al., 2000). The results demonstrated that this method was more effective in the suppression of tumor growth than conventional therapy. However, the effects of this method...
on lung cancer remain to be evaluated.

In this study, we aimed to evaluate the effectiveness of ginsenoside Rg3 alone or in combination with cyclophosphamide (CPA) on the tumor growth and angiogenesis in human lung cancer.

MATERIALS AND METHODS

Ginsenoside Rg3, provided by the Department of Basic Medicine of Shandong University, was extracted from American ginseng with ≥99.5% of purity quotient. Six-week old female athymic mice were purchased from the department of Experimental Animal Center of Shandong University. The mouse monoclonal antibodies specific to CD31, vascular endothelial cell growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) were purchased from Santa Cruz Co. (Santa Cruze, USA).

Human lung cancer cell line A549 was obtained from the Department of Basic Medicine of Shandong University and cultured in RPMI1640 supplemented with 10% fetal bovine serum. 28 female athymic mice were subcutaneously transplanted with 0.2 ml (1 x 10^7/ml) A549 cell suspension in the armpit of right anterior limb. These mice were randomly divided into 4 groups (n = 14 for each): Ginsenoside Rg3 group, CPA group, ginsenoside Rg3 plus CPA group and control group. Ginsenoside Rg3 was intraperitoneally administrated at a dose of 3.0 mg/kg (once/day for 10 days) and CPA of 20.0 mg/kg (once/day for 10 days). The mice in the control group received saline. Seven mice selected from each group were sacrificed 18 days later. The survival time of the remaining 7 mice in each group was recorded. During the experiment, the survival time was recorded within forty days after tumor transplantation. Additionally, the life elongation rate was analyzed. Tumor tissues were fixed immediately in 10% paraformaldehyde and embedded in paraffin. Proliferative activity of lung cancer cells was evaluated by immunohistochemical staining with mouse monoclonal PCNA antibody (1:100) and the number of positive cells was counted at ×400 magnifications. Subsequently, proliferating cell nuclear antigen labeling index (PCNALI) was calculated.

Vascularization was expressed by MVD (micro-vascular density). The micro-vascular was evaluated by immunostaining of endothelium with mouse monoclonal CD31-PECAM antibody (1:100). The number of CD31 immunostained blood vessels was quantified at ×200 magnification. The values from five different fields were averaged and presented as mean ± standard deviation. VEGF positive cells were stained with yellow brown in the cytoplasm. The intensity of the immunoreactive reaction were graded as 0, no immunoreactivity; 1, weak intensity; 2, moderate intensity; 3, strong intensity. Positive percentage were graded as 0, <10%; 1, 10 to 24%; 2, 25 to 49%; 3, 50 to 75%; 4, ≥75. After adding the scores of intensity and positive percentage, we rescaled to score 0 to 1 as negative (-), 2 to 3 as weak expression (1+), 4 to 5 as moderate expression (2+) and above 5 as strong expression (3+), and the immunoreactivity was scored semi quantitatively as the intensity of the immunoreactive reaction and positive percent of tumor cells.

Statistical analysis

The results were expressed with mean ± standard deviation. Statistical analysis was performed by LSD test and one way analysis of variance for multiple comparisons in evaluation of tumor weight and number of living day. Nemenyi test for two comparisons and Kruskal Wallis test for multiple comparisons were performed in the analysis of PCNALI, MVD (micro-vascular density) and VEGF. A value of P<0.05 was considered as statistically significant.

RESULTS

Effects of ginsenoside Rg3 and CPA on life elongation

40 days after tumor transplantation, the number of mice that survived in ginsenoside Rg3, CPA, ginsenoside Rg3 plus CPA and control groups was 3, 2, 3 and 0, respectively. The survival time of mice with lung cancer in the ginsenoside Rg3, CPA and ginsenoside Rg3 plus CPA groups was longer than in the control group and the life elongation rate reached 98.2% in the mice of ginsenoside Rg3 plus CPA group (Table 1). The results demonstrate that ginsenoside Rg3 prolonged survival time of mice with lung cancer. Furthermore, the ginsenoside Rg3 and CPA conferred the synergistic therapeutic effects on the lung cancer.

Effects of ginsenoside Rg3 and CPA on tumor cell proliferation and angiogenesis

Table 2 and Figure 1 show that the number of PCNA positive cells and PCNALI in the treated groups was lower than that in the control group. These findings show that the ginsenoside Rg3, CPA or ginsenoside Rg3 in combination with CPA could inhibit the proliferation of A549 cells which leads to the suppression of tumor growth.

The density of blood vessels in tumor tissues was assessed by CD31-PECAM immunostaining. The MVD in the ginsenoside Rg3, CPA and ginsenoside Rg3 plus CPA groups was significantly lowered when compared with control group. Furthermore, in the ginsenoside Rg3 and ginsenoside Rg3 plus CPA groups, it was lower than CPA group (Table 2 and Figure 2). VEGF positive cells found in the ginsenoside Rg3, CPA and ginsenoside Rg3 plus CPA groups were markedly decreased when compared with control group, and there was no significant difference among the treated groups (Table 3 and Figure 3). The results show that ginsenoside Rg3 inhibited tumor angiogenesis and the angiostatic effects of ginsenoside Rg3 were improved by CPA.

DISCUSSION

Chemotherapy is the treatment of choice for a variety of malignant tumors, which together with surgery and radiotherapy constitute the traditional therapeutic methods for cancer. Although, chemotherapy is effective in combating against the tumor growth and metastasis, the mortality of cancer remains high. For example, 5-year survival rate of lung cancer remains low after conventional treatment (Davis et al., 2004). Thus, numerous studies have been conducted to explore novel therapies for cancers (Nguyen et al., 1998). Anti-angiogenesis is a promising
Table 1. Effect of ginsenoside Rg3 and CPA on life elongation of mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of mice</th>
<th>Living day</th>
<th>Life elongation rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>7</td>
<td>13.59±6.21</td>
<td>-</td>
</tr>
<tr>
<td>Rg3</td>
<td>7</td>
<td>23.81±9.22</td>
<td>74.5</td>
</tr>
<tr>
<td>CPA</td>
<td>7</td>
<td>25.89±10.08</td>
<td>90.2</td>
</tr>
<tr>
<td>CPA+Rg3</td>
<td>7</td>
<td>27.22±8.11</td>
<td>98.2</td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.01 vs. control group.

Table 2. Inhibitory effects of ginsenoside Rg3 and CPA on tumor cell proliferation and angiogenesis (PCNALI and MVD in different groups).

<table>
<thead>
<tr>
<th>Group</th>
<th>PCNALI (%)</th>
<th>Number of vessel (MVD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>69.1±10.7</td>
<td>28.3±3.1</td>
</tr>
<tr>
<td>Rg3</td>
<td>53.5±14.9*</td>
<td>23.0±2.64**</td>
</tr>
<tr>
<td>CPA</td>
<td>43.1±12.3**</td>
<td>18.9±2.14**</td>
</tr>
<tr>
<td>CPA+Rg3</td>
<td>35.5±12.7**</td>
<td>10.8±2.88**</td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.01 vs control group. PCNALI, proliferating cell nuclear antigen labeling index; MVD, microvessel density.

Figure 1. Immunohistochemical staining of PCNA. PCNA positive cells have yellow brown granules in nucleus. A: Control group; B: ginsenoside Rg3 group; C: CPA group; D: ginsenoside Rg3 plus CPA group (magnification ×200).

Figure 2. Immunohistochemical staining of CD31. The blood vessels in tumor tissues are stained with yellow brown. A: Control group; B: ginsenoside Rg3 group; C: CPA group; D: ginsenoside Rg3 plus CPA group (magnification ×200).

approach for the treatment of lung cancer. The rationale, as set forth by Folkman and others (Fukushima, 1983), states that establishing a state of counterbalancing between apoptosis and tumor cell proliferation by inhibiting angiogenesis induced by tumor and thus depriving tumors of essential nutrients and oxygen, leading to a quiescent state in which tumor expansion is stalled (Ellis et al., 2001). Ginsenoside Rg3, the major active component of ginseng, exerts angiosuppressive effects in numerous cancers (Yue et al., 2006; Chen et al., 2005). In this study, the results show that ginsenoside Rg3 inhibited the tumor growth and angiogenesis in lung cancer. Studies have confirmed that VEGF played an important role in the angiogenesis, and its expression was correlated with MVD (Maria et al., 2005). Our study discloses that ginsenoside Rg3 significantly
Table 3. Inhibitory effect of ginsenoside Rg3 and CPA on expression of VEGF.

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of mice</th>
<th>-</th>
<th>+</th>
<th>++</th>
<th>+++</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Rg3</td>
<td>7</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>CPA</td>
<td>7</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>CPA+Rg3</td>
<td>7</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>&lt;0.05*</td>
</tr>
</tbody>
</table>

*P values vs. control group. VEGF, vascular endothelial cell growth factor.

decreased the expression of VEGF in lung cancer. These findings indicate that ginsenoside Rg3 could inhibit the tumor growth through its angiosuppressive effects. To prove the anti-cancer effects of ginsenoside Rg3, we assess the proliferative activity of lung cancer cells through PCNALI. PCNA is the polymerase δ accessory protein and synthesized in the early G1 and S phases of cell cycle when DNA synthesis is dominant. Therefore, PCNA can reflect the DNA replication. Furthermore, the metabolism and DNA replication in tumor cells represent the proliferative activity. Thus, PCNA is frequently used as an indicator of proliferative activity of tumor cells (Isozaki et al., 1996; Niu et al., 2002). Ginsenoside Rg3 inhibits the PCNA expression that causes the reduced proliferative activity of lung cancer. Based on these results, we postulate that ginsenoside Rg3 may be an effective inhibitor of angiogenesis. However, in contrast to the data generated from animal studies, the previous results of various clinical trials aiming at evaluating angiogenic inhibitors in cancer therapy have been equivocal. A strategy combining continuous low dose chemotherapy and anti-angiogenic therapy has been developed recently and used in the experimental treatment of malignant tumors such as breast cancer, retinoblastoma, lymphoma and leukemia (Overmoyer et al., 2007; Bello et al., 2001; Morioka et al., 2003). The combination of low dose chemotherapy and anti-angiogenic therapy was more effective in suppressing cancer growth than conventional chemotherapy.

Conclusions

Taken together, this study suggests that ginsenoside Rg3, alone or in combination with CPA inhibits cancer growth and angiogenesis in lung cancer. Furthermore, the combination of ginsenoside Rg3 and CPA confers synergistic angiosuppressive effects and improves the quality of life of mice with lung cancer. The combination of chemotherapy and antiangiogenic therapy may be a promising candidate in the experimental treatment of lung cancer.

REFERENCES


